Fingolimod cuts multiple sclerosis relapses in pediatric patients

September 13, 2018

(HealthDay)—Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the Sept. 13 issue of the New England Journal of Medicine.

Tanuja Chitnis, M.D., from Massachusetts General Hospital in Boston, and colleagues compared outcomes in patients aged 10 to 17 years with relapsing who were randomized to receive (107 participants) or interferon beta-1a (108 participants) for up to two years.

The researchers found that the adjusted annualized relapse rate was 0.12 with fingolimod and 0.67 with interferon beta-1a. The annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging was 4.39 with fingolimod and 9.27 with interferon beta-1a. Adverse events occurred in 88.8 percent of patients receiving fingolimod and 95.3 percent receiving interferon beta-1a. Serious adverse events occurred in 18 patients (16.8 and 6.5 percent, respectively). These serious adverse events included seizures (four patients), infection (four patients), and leukopenia (two patients) in the fingolimod group and infection (two patients) and supraventricular tachycardia (one patient) in the beta-1a group.

"Longer studies are required to determine the durability and safety of fingolimod in pediatric multiple sclerosis," the authors write.

Several authors disclosed financial ties to Novartis, which manufactures fingolimod and funded the study.

Explore further: Study of daclizumab yields mixed results in multiple sclerosis

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Study of daclizumab yields mixed results in multiple sclerosis

October 8, 2015
(HealthDay)—Multiple sclerosis patients taking daclizumab high yield process (HYP), a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling, ...

Fingolimod in new therapeutic indication: Added benefit not proven

October 10, 2014
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...

Rituximab tops other disease-modifying tx options in MS

January 9, 2018
(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...

Fingolimod in RRMS: Indication of added benefit in certain patients

July 6, 2015
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...

Fingolimod in multiple sclerosis: No hint of added benefit in new therapeutic indication

March 8, 2016
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification ...

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

June 16, 2016
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...

Recommended for you

Use of electrical brain stimulation to foster creativity has sweeping implications

September 18, 2018
What is creativity, and can it be enhanced—safely—in a person who needs a boost of imagination? Georgetown experts debate the growing use of electrical devices that stimulate brain tissue, and conclude there is potential ...

Engineers decode conversations in brain's motor cortex

September 18, 2018
How does your brain talk with your arm? The body doesn't use English, or any other spoken language. Biomedical engineers are developing methods for decoding the conversation, by analyzing electrical patterns in the motor ...

Team identifies brain's lymphatic vessels as new avenue to treat multiple sclerosis

September 17, 2018
Lymphatic vessels that clean the brain of harmful material play a crucial role in the development and progression of multiple sclerosis, new research from the University of Virginia School of Medicine suggests. The vessels ...

Circuit found for brain's statistical inference about motion

September 17, 2018
As the eye tracks a bird flying past, the muscles that pan the eyeballs to keep the target in focus set their pace not only on the speed they see, but also on a reasonable estimate of the speed they expect from having watched ...

Mouse study reveals that activity, not rest, speeds recovery after brain injury

September 17, 2018
When recovering from a brain injury, getting back in the swing of things may be more effective than a prolonged period of rest, according to a new Columbia study in mice. These findings offer a compelling example of the brain's ...

Fine-tuned sense of smell relies on timing

September 17, 2018
If you can tell the difference between a merlot and a cabernet franc just by smell, it's probably all in the timing.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.